Comments on: Accelerator Bankrolls New Company, Mirina, To Develop MicroRNA-Blocking Drugs http://www.xconomy.com/seattle/2008/08/15/accelerator-bankrolls-new-company-mirina-to-develop-microrna-blocking-drugs/ Business + Technology in the Exponential Economy Sun, 22 Nov 2009 16:55:51 -0600 http://wordpress.org/?v=2.8.6 hourly 1 By: Rebecca Zacks http://www.xconomy.com/seattle/2008/08/15/accelerator-bankrolls-new-company-mirina-to-develop-microrna-blocking-drugs/comment-page-1/#comment-26126 Rebecca Zacks Sat, 16 Aug 2008 15:08:20 +0000 http://www.xconomy.com/?p=3759#comment-26126 Bob, Luke actually filed this story before heading out on vacation, and so was out of town when the Nanogen/Elitech deal was announced. Thanks much for bringing it to our attention. Bob,
Luke actually filed this story before heading out on vacation, and so was out of town when the Nanogen/Elitech deal was announced. Thanks much for bringing it to our attention.

]]> By: Bob http://www.xconomy.com/seattle/2008/08/15/accelerator-bankrolls-new-company-mirina-to-develop-microrna-blocking-drugs/comment-page-1/#comment-26075 Bob Fri, 15 Aug 2008 16:48:06 +0000 http://www.xconomy.com/?p=3759#comment-26075 Not enough research done on this article! Nanogen is not "public" anymore, it got "acquired"... Today's (Aug 15) news: "Nanogen said today after market close that it has signed a merger agreement with Paris-based diagnostic firm the Elitech Group that is structured as a reverse acquisition of Nanogen by the privately held Elitech. Under the terms of the agreement, Nanogen said that Elitech shareholders are expected to receive shares of Nanogen common stock valued at €66.5 million ($98.5 million). " Not enough research done on this article! Nanogen is not “public” anymore, it got “acquired”…

Today’s (Aug 15) news:
“Nanogen said today after market close that it has signed a merger agreement with Paris-based diagnostic firm the Elitech Group that is structured as a reverse acquisition of Nanogen by the privately held Elitech.

Under the terms of the agreement, Nanogen said that Elitech shareholders are expected to receive shares of Nanogen common stock valued at €66.5 million ($98.5 million). “

]]>